Analyst Price Target is $22.50
▲ +111.27% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Gossamer Bio in the last 3 months. The average price target is $22.50, with a high forecast of $26.00 and a low forecast of $16.00. The average price target represents a 111.27% upside from the last price of $10.65.
Current Consensus is
The current consensus among 5 investment analysts is to buy stock in Gossamer Bio. This Buy consensus rating has held steady for over two years.
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.